Abstract
Platinum-based chemotherapy is the current standard of care for patients with non-small cell lung cancer (NSCLC) whose disease progresses on osimertinib. However, osimertinib-relapsed disease may still be sensitive to EGFR and/or MET inhibition, as demonstrated by the antitumor activity observed with amivantamab and lazertinib in this setting (Cho Ann Oncol 2020; 31:S813; 1258O). Combining platinum-based chemotherapy with targeted inhibition of EGFR/MET signaling through the action of amivantamab and lazertinib may lead to improved outcomes in EGFR tyrosine kinase inhibitor (TKI)-relapsed/refractory disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
